Clinical Trial Update: Efficacy and Safety of Risperidone Compared With Placebo in the Treatment of Psychotic Symptoms in Patients With Alzheimer's Disease [Phase 3]

View source ↗

Summary

Phase 3 trial comparing risperidone with placebo for psychotic symptoms in Alzheimer's disease. The study evaluated efficacy and safety in this population.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• RISPERIDONE (RISPERIDONE)

Snippet

Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Conditions: Dementia, Alzheimer Disease | Phase 3 | Status: COMPLETED